Key Insights

Highlights

Treatment Research

3 treatments under study, led by Osimertinib

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Active Not Recruiting1
Not Yet Recruiting1
Unknown1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07491211Active Not Recruiting

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

NCT06818955Phase 2Not Yet Recruiting

Orlistat Overcoming Third-generation EGFR-TKI Resistance

NCT05458726Phase 2Unknown

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

Showing all 3 trials

Research Network

Common Treatments

  • Osimertinib2
  • Intracranial Stereotactic Radiotherapy1
  • Orlistat1

Active Sponsors

  • Peking Union Medical College1
  • Ping Peng1
  • Hubei Cancer Hospital1
  • Fudan University1

Top Investigators

Related Conditions

  • Nsclc Advanced Nonsmall Cell Lung Cancer1
  • Stereotactic Radiation1
  • Egfr T790m1
  • Brain Metastases From Nonsmall Cell Lung Cancer Nsclc1
  • Ddpcr1

Activity Timeline